Trial reportDiabetes technology & therapeutics2019
Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia.
Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Diabetes technology & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02302963 (Unified Safety System), which is not on this map. Cited by 26 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Unified Safety System (USS) Virginia Closed-Loop Versus Sensor Augmented Pump Therapy for Hypoglycemia Reduction in Type 1 Diabetes
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Hybrid closed-loop insulin delivery improves glycaemic control compared with sensor-augmented pump therapy: A meta-analysis of 'free-living' randomised trials in type 1 diabetes.Diabetic medicine : a journal of the British Diabetic Association · 2026Pooled it
- A systematic review: Cost-effectiveness of continuous glucose monitoring compared to self-monitoring of blood glucose in type 1 diabetes.Endocrinology, diabetes & metabolism · 2022Pooled it
- Trial
- Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial.The Lancet. Digital health · 2020Trial
- Artificial Pancreas: The First 20 Years.Journal of diabetes science and technology · 2025Article
- The challenge of assessing impaired awareness of hypoglycaemia in diabetes in the era of continuous glucose monitoring: A narrative review of evidence and translation into clinical practice.Diabetes, obesity & metabolism · 2025Review
- Efficacy of automated insulin delivery systems in people with type 1 diabetes: a systematic review and network meta-analysis of outpatient randomised controlled trials.EClinicalMedicine · 2025Article
- The impact of technology on impaired awareness of hypoglycaemia in type 1 diabetes.Therapeutic advances in endocrinology and metabolism · 2025Review
- 7. Diabetes Technology: Standards of Care in Diabetes-2025.Diabetes care · 2025Review
- Elevated urinary albumin predicts increased time in range after initiation of SGLT2 inhibitors in individuals with type 1 diabetes on sensor-augmented pump therapy.Diabetology international · 2024Article
- Evaluation of hybrid closed-loop insulin delivery system in type 1 diabetes in real-world clinical practice: One-year observational study.World journal of diabetes · 2024Article
- 7. Diabetes Technology: Standards of Care in Diabetes-2024.Diabetes care · 2024Review
- When Type 1 Diabetes Meets Dementia: Practical Strategies to Help Patients and Their Loved Ones.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
- Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility.Journal of diabetes science and technology · 2023Review
- Real-life data of hypoglycemic events in children and adolescents with type 1 diabetes.BMJ open diabetes research & care · 2023Article
- Real-World User and Clinician Perspective and Experience with MiniMed™ 780G Advanced Hybrid Closed Loop System.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Automated Insulin Delivery for Hypoglycemia Avoidance and Glucose Counterregulation in Long-Standing Type 1 Diabetes with Hypoglycemia Unawareness.Diabetes technology & therapeutics · 2023Article
- 7. Diabetes Technology: Standards of Care in Diabetes-2023.Diabetes care · 2023Review
- Effectiveness and safety of a model predictive control (MPC) algorithm for an artificial pancreas system in outpatients with type 1 diabetes (T1D): systematic review and meta-analysis.Diabetology & metabolic syndrome · 2022Review
- Real-World Experience With Automated Insulin Pump Technology in Veterans With Type 1 Diabetes.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Stacey M Anderson1 Center for Diabetes Technology, University of Virginia, Charlottesville, VA.
Bruce A Buckingham2 Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
Marc D Breton1 Center for Diabetes Technology, University of Virginia, Charlottesville, VA.
Jessica L Robic1 Center for Diabetes Technology, University of Virginia, Charlottesville, VA.
Charlotte L Barnett1 Center for Diabetes Technology, University of Virginia, Charlottesville, VA.
Christian A Wakeman1 Center for Diabetes Technology, University of Virginia, Charlottesville, VA.
Mary C Oliveri1 Center for Diabetes Technology, University of Virginia, Charlottesville, VA.
Sue A Brown1 Center for Diabetes Technology, University of Virginia, Charlottesville, VA.
Trang T Ly2 Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
Paula K Clinton2 Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
Liana J Hsu2 Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
Ryan S Kingman2 Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
Lisa M Norlander2 Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
Sarah E Loebner2 Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
Suzette Reuschel-DiVirglio2 Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
Boris P Kovatchev1 Center for Diabetes Technology, University of Virginia, Charlottesville, VA.
Stanford Medicine · USUniversity of Virginia · US
Funding
NIDDK NIH HHS DP3 DK101055
Abstract
PubMed holds no abstract for this paper.
Indexed as
Insulin Infusion SystemsAdultBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Equipment DesignFemaleHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulinMaleBlood GlucoseHypoglycemic AgentsInsulinArtificial pancreasClosed-loop systemsHypoglycemiaType 1 diabetes
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
NCT02302963ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.